Introduction
intermuscular adiposity, Treatment-related, hypoglycemia, weight gain, insulin secretion deficiencies, T2DM, diabetes
DISEASE, HYPOGLYCEMIA, INSULIN RESISTANCE, TYPE 2 DIABETES, COMPLICATIONS, DIABETES
The goal of type 2 diabetes (T2DM) management is to sustain the quality of life (QoL). Many criteria, including gender, age, glycemic control status, disease duration, complications of diabetes, and patient’s physical status, must be considered to achieve these goals. Treatment-related QoL has always been considered significant when selecting glucose-lowering medications since it has been identified as an important component associated with patient motivation and adherence [T2DM is a condition that is intrinsically related to aging, with a dramatically raised prevalence in people getting older. This is mainly a result of insulin secretion deficiencies, insulin resistance (associated with increasing visceral, intramuscular, and intermuscular adiposity), cellular senescence, and lifestyle factors, especially lack of physical activity, typically in the aged population [In Pakistan, the quality of life (QoL) of people with diabetes can be influenced by various factors such as socioeconomic status, access to treatment, cultural beliefs, and dietary habits. These factors may differ from other regions and can affect QoL differently. Studies suggest that QoL for diabetes patients in Pakistan [A study reported that 36.5% of the patients with diabetes had not obtained conventional anti-diabetic treatment. This was likely due to the inconvenient usage effects, including limited duration of the activity, insufficient efficacy, and various other side effects, for instance, weight gain, digestive issues, and hypoglycemia [Sitagliptin binds to DPP-4 and prevents the breakdown of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). GIP and GLP-1 are both kinds of intestinal incretin hormones that help stimulate insulin secretion while suppressing glucagon secretion [